Exicure's Reverse Merger Round

Exicure raised a round of funding on September 28, 2017. Investors include Max-1 Acquisition Corporation.

Exicure, formerly AuraSense Therapeutics, is developing a new class of immunomodulatory and gene silencing drugs against validated targets. The company's 3-dimensional, spherical nucleic acid (SNA) ar…

Articles about Exicure's Reverse Merger Round: